Business Wire

Reply AI Film Festival - Announced the Winners of the First International Festival for Short Films Made With Artificial Intelligence

4.9.2024 10:30:00 EEST | Business Wire | Press release

Share

The winners of the first edition of the Reply AI Film Festival have been announced, the competition for authors of original short films made with Artificial Intelligence (AI), conceived by Reply, a leading international group in the creation of new business models enabled by AI and Digital Media. The awards event, organized in collaboration with Mastercard, was held at the Priceless lounge of the Hotel Excelsior in Venice.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904521664/en/

Reply presents the inaugural Reply AI Film Festival, an international competition where Artificial Intelligence (AI) serves not only as a catalyst for innovation in the realm of creative storytelling but also as a tool for fostering inclusivity among younger generations in video and film production. (Photo: Business Wire)

The award for Best Short Film was given to 'To Dear Me' byGisele Tong, which tells the story of a young woman, tormented by memories of her parents' divorce and her mother's loneliness, struggling with love, feeling lost and distrustful, until she realizes that finding her true self is the key to healing and moving forward.

Second place went to 'One Way' byEgor Kharlamov, a story about how life can offer a second chance even when it seems there's nothing left to lose. The film ponders on what the price of this second opportunity is.

Third place was awarded to 'Jinx' byMansha Totla, thatfocuses on the memories of World War II through the voice of the main character, Jinx Akerkar, and emphasizes on the fragility of life. An intense dedication to those who lost their lives during the war and those who are still affected by that loss today.

The three winning short films were built around the theme "Synthetic Stories, Human Hearts" and were selected from the twelve finalists by an international jury, which was composed of Adam Kulick, Caleb & Shelby Ward, Denise Negri, Filippo Rizzante, Flavio Natalia, Julien Vallée & Eve Duhamel, Monica Riccioni, Paul Trillo, and Rob Minkoff.

To identify the finalists, the jurors reviewed over 1,000 short films submitted from more than 59 countries, including the USA, UK, Italy, Germany, Spain, France, Brazil, China, India, and Korea. AI artists, directors, writers, animators, VFX artists, but also amateurs were in the talent pool who were competing in the contest, preferring the Narratives and Experimental categories, chosen respectively by 38% and 36% of participants - followed by Documentary (14%) and Pilots (12%).

“To Dear Me, inspired by the animated short film Liebestraum by Yan Xiaoxuan, is a letter written by the creative team to girls and women everywhere. The story condenses the experiences of the many girls and women around them - their mothers, friends, and students. Many of these women carry the scars and flaws of their upbringing, lacking love, yearning for love, but unsure how to love. They often swing between love and hatred, desperately trying to hold onto anyone who loves them, investing all their emotions until they get hurt and become afraid to open their hearts again. They can even lose themselves in a web of false pretenses, doubting if they will ever find true love or even retain the ability to express it properly. With this short film, I want to tell these tender souls around me that even if we lose the love of the world, we must still love ourselves. I encourage them to take a good look at their own lives - the good and the bad - as these precious experiences have shaped each of us into the unique individuals we are. Rescue your past self and empower your present self. My dear girls, it has not been easy on this journey of growth, but remember to love yourselves well and give yourselves a warm embrace,” commented Gisele Tong, who was awarded first place in the competition.

“We are very happy to be part of the festival! This is a great honor and joy for us! Technology is moving forward and the fact that today there is such an opportunity to use artificial intelligence as a tool in the creation of movies and animation, is an incredible breakthrough. A story in a movie can now be told by anyone, that's great! It is important to remember that any technology is a tool in the hands of man, an incredibly powerful tool and let it serve for the benefit of mankind. Thank you to the festival for highlighting the first steps of new opportunities!” commented Egor Kharlamov, the second-place winner.

“The Reply AI Film Festival has been an incredible experience and I’m so happy that my film, ‘JINX’ was selected as a finalist. The festival team has been so attentive and the appreciation of my work has motivated me to further believe in myself. I was stuck for the past 3 years as I didn’t simply want to fill in the gaps of my film with random stock footage of the war. Thus, the most significant thing about my film was the use of AI to create WW2 footage that is authentic to my subject’s story. I believe that in the future, AI will transform the filmmaking industry and it’ll be interesting to see how we incorporate AI's capabilities with our human vision and artistic intuition,” commented Mansha Totla, the third-place winner.

“The winners of the Reply AI Film Festival demonstrate how Artificial Intelligence enables the creation of new narratives, innovative, and visually captivating content, while maintaining the essential human element—the vision, heart, and soul of a film,” said Filippo Rizzante, CTO of Reply. “The Reply AI Film Festival has become an important opportunity to highlight innovation and creativity, offering young talent the chance to immerse themselves in new technologies, acquire advanced skills, and create new, more accessible and sustainable creative scenarios.”

“We are pleased to have hosted in Venice the awards event of the Reply AI Film Festival, a competition that enhances the creativity of young film talents, offering them a unique opportunity for interaction and expression,” said Luca Fiumarella, Head of Marketing Italy at Mastercard. “We are committed to promoting initiatives where technology combines with great passions, creating new opportunities to bring people closer to the world of art and cinema. Our goal is to make artistic production more accessible and inclusive, using technological innovation to fuel creativity and support new generations in pursuing their aspirations.”

The Reply AI Film Festival was created by Reply as part of its program to promote new technologies among younger generations. The goal is to foster a culture of innovation and provide a new, stimulating space for experimentation, offering a space where AI can be put to the test as an ally of human creativity and demonstrate that the synergy between people and technologies can enable new scenarios that are more accessible to anyone who possesses the spark of creativity. The competition is part of the Reply Challenges, a program of technological and creative competitions that testify to Reply's commitment to developing innovative educational models capable of engaging new generations. Today Reply's Challenges have a community of more than 150,000 participants.

To see the winning short films and finalists, visit aiff.reply.com.

Reply

Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

Mastercard

Mastercard is an international payments technology company. Our goal is to create connections and promote an inclusive digital economy from which everyone can benefit, wherever they are, through secure, simple, fast and accessible transactions. By being able to rely on secure data and networks, partnerships and passion, and our products and solutions, we help consumers, financial institutions, governments and businesses reach their full potential. With a presence in more than 210 countries and territories, we are building a more sustainable world that offers priceless opportunities for all. www.mastercard.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904521664/en/

Contacts

Reply
Fabio Zappelli
f.zappelli@reply.com
Irene Caia
i.caia@reply.com

Mastercard
Giuliana Abbate
E. Giuliana.Abbate@mastercard.com

Omnicom PR Group
Ufficio Stampa Mastercard
T. 02 6241 19
E. mln.mastercard@fleishmaneurope.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye